Cardiol Therapeutics to Present Cardiovascular Pipeline Update at TD Cowen Health Care Conference
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cardiol Therapeutics ( (TSE:CRDL) ) just unveiled an update.
Cardiol Therapeutics Inc., a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease, will present at the TD Cowen 46th Annual Health Care Conference in Boston. Management is scheduled to deliver a presentation on March 4, 2026, at 10:30 a.m. EST, with a live webcast and replay available via the company’s investor relations website.
The appearance provides Cardiol with a platform to highlight progress in its Phase III MAVERIC trial in recurrent pericarditis, its completed Phase II ARCHER study in acute myocarditis, and its ongoing development of CRD-38 for inflammatory heart disease. The conference presentation underscores the company’s efforts to raise its visibility among investors and healthcare stakeholders as it advances late-stage cardiovascular programs with orphan drug backing in the U.S.
The most recent analyst rating on (TSE:CRDL) stock is a Buy with a C$9.00 price target. To see the full list of analyst forecasts on Cardiol Therapeutics stock, see the TSE:CRDL Stock Forecast page.
Spark’s Take on TSE:CRDL Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRDL is a Neutral.
The score is held down primarily by very weak financial performance (pre-revenue profile, large ongoing losses, and substantial cash burn with shrinking equity), which increases financing and dilution risk despite low debt. Technicals provide only a modest offset due to improving short-term momentum, while valuation remains unattractive because the company is loss-making and offers no dividend support.
To see Spark’s full report on TSE:CRDL stock, click here.
More about Cardiol Therapeutics
Cardiol Therapeutics Inc. is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead small-molecule candidate, CardiolRx, targets inflammasome pathway activation and is being evaluated in pericarditis and acute myocarditis, while a second program, CRD-38, is aimed at inflammatory heart disease including heart failure.
Average Trading Volume: 85,873
Technical Sentiment Signal: Sell
Current Market Cap: C$153M
See more insights into CRDL stock on TipRanks’ Stock Analysis page.
